- decreased level of surface class I molecules / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased IgG level / MGI
- abnormal pancreas morphology / MGI
- decreased susceptibility to bacterial infection / MGI
- increased IgM level / MGI
- decreased susceptibility to autoimmune diabetes / MGI
- decreased circulating serum albumin level / MGI
- increased T-helper 1 cell number / MGI
- abnormal interleukin level / MGI
- abnormal tumor necrosis factor level / MGI
- increased susceptibility to infection induced morbidity/mortality / MGI
- absent CD8-positive, alpha-beta T cells / MGI
- abnormal pancreatic beta cell morphology / MGI
- abnormal T cell number / MGI
- insulitis / MGI
- abnormal neuron proliferation / MGI
- abnormal immune system morphology / MGI
- abnormal spleen morphology / MGI
- abnormal immune system cell morphology / MGI
- postnatal growth retardation / MGI
- abnormal immune system physiology / MGI
- reduced fertility / MGI
- abnormal spleen periarteriolar lymphoid sheath morphology / MGI
- abnormal spleen marginal zone morphology / MGI
- abnormal CD4-positive, alpha beta T cell morphology / MGI
- abnormal T cell physiology / MGI
- abnormal B cell physiology / MGI
- abnormal immune system organ morphology / MGI
- abnormal cytokine secretion / MGI
- decreased susceptibility to parasitic infection / MGI
- increased susceptibility to parasitic infection / MGI
- abnormal CD4-positive, alpha-beta T cell physiology / MGI
- increased CD4-positive, alpha beta T cell number / MGI
- decreased CD4-positive, alpha beta T cell number / MGI
- increased CD8-positive, alpha-beta T cell number / MGI
- abnormal spleen B cell follicle morphology / MGI
- absent spleen germinal center / MGI
- decreased IgG1 level / MGI
- abnormal lymph node cell ratio / MGI
B6.Cg-B2mtm1Unc H2-Ab1tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl
Status | Available to order |
EMMA ID | EM:05777 |
International strain name | B6.Cg-B2mtm1Unc H2-Ab1tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl |
Alternative name | SURE-L1/Her2-neu |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | B2mtm1Unc, |
Gene/Transgene symbol | B2m |
Information from provider
Provider | Yu Chun LONE |
Provider affiliation | INSERM U1014 |
Genetic information | HLA-A2+/+, HLA-DR1+/+, Her2-neu+/+, IAbeta°, b2m° |
Phenotypic information | HLA-A2+, HLA-DR1+, Her2-neu+, IAbeta°, b2m° |
Breeding history | Cofounder strain: B6.FVB-Tg Her2-neu, N10 C57BL/6 Cofounder strain (SURE-L1): HLA-A2/HLA-DR1/IAbeta°/ b2m°, N6 C57BL/6 |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | yes |
Immunocompromised | yes |
Information from EMMA
Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
Animals used for archiving | homozygous 0, homozygous 0 |
Breeding at archiving centre | Heterozygous knock-out for B2m (beta2m); homozygous knock-out for H2-Ab1 (AbetaA); transgenic for Tg(HLA-A/H2-D/B2M)1Bpe (HLAA2), Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma (HLADRA1) and Tg(MMTV-neu/OT-I/OT-II)CBnel (Her2-neu). |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Immunodeficiency by defective expression of MHC class I / Orphanet_34592
- Variant ABeta2M amyloidosis / Orphanet_314652
MGI phenotypes (allele matching)
Literature references
- A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
- Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.;Wall Erika M, Milne Katy, Martin Michele L, Watson Peter H, Theiss Patty, Nelson Brad H, ;2007;Cancer research;67;6442-50; 17616705
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).